Moderna, Inc Closed Now

Introduction
Moderna, Inc. is a pioneering American biotechnology company specializing in messenger RNA (mRNA) therapeutics and vaccines. Founded in 2010, Moderna gained global recognition during the COVID-19 pandemic for developing one of the first mRNA-based vaccines, mRNA-1273 (Spikevax). The company’s innovative platform focuses on leveraging mRNA technology to create a new class of medicines across infectious diseases, immuno-oncology, rare diseases, and cardiovascular disorders.

Mission and Vision

• Mission: To deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.

• Vision: To harness the power of mRNA technology to improve human health and address the world’s most challenging medical needs.

Products and Services

• Vaccines: COVID-19 vaccine (Spikevax) and pipeline vaccines for influenza, RSV, CMV, HIV, and other infectious diseases.

• Rare Diseases: Experimental mRNA therapies targeting metabolic and genetic disorders.

• Immuno-Oncology: Investigational mRNA-based cancer vaccines and immunotherapies.

• Cardiovascular: Therapies designed to regenerate heart tissue and treat cardiovascular conditions.

• Respiratory Diseases: A growing pipeline targeting viral respiratory infections.

Growth and Innovation
Moderna revolutionized medicine by proving the potential of mRNA vaccines at a global scale. Its rapid response to COVID-19 established it as a household name and a biotech leader. The company continues to expand its mRNA platform beyond vaccines into therapeutics. Moderna is also investing in AI, machine learning, and digital technologies to accelerate R&D and manufacturing.

Global Impact
Moderna has had a profound global health impact, particularly through the COVID-19 vaccine, which has saved millions of lives worldwide. The company is expanding collaborations with governments and organizations to improve pandemic preparedness and equitable vaccine distribution. Moderna also maintains a strong commitment to sustainability and global access to innovative medicines.